166 related articles for article (PubMed ID: 24437461)
1. Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.
Dézsi L; Vécsei L
Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):409-24. PubMed ID: 24437461
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
Müller T
Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
[TBL] [Abstract][Full Text] [Related]
3. Designing prodrugs for the treatment of Parkinson's disease.
Sozio P; Cerasa LS; Abbadessa A; Di Stefano A
Expert Opin Drug Discov; 2012 May; 7(5):385-406. PubMed ID: 22494466
[TBL] [Abstract][Full Text] [Related]
4. Levodopa in Parkinson's disease: from the past to the future.
Pezzoli G; Zini M
Expert Opin Pharmacother; 2010 Mar; 11(4):627-35. PubMed ID: 20163273
[TBL] [Abstract][Full Text] [Related]
5. Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson"s disease patients experiencing motor fluctuations with levodopa.
Okereke CS
J Pharm Pharm Sci; 2002; 5(2):146-61. PubMed ID: 12207867
[TBL] [Abstract][Full Text] [Related]
6. Safinamide for the treatment of Parkinson's disease.
Dézsi L; Vécsei L
Expert Opin Investig Drugs; 2014 May; 23(5):729-42. PubMed ID: 24650154
[TBL] [Abstract][Full Text] [Related]
7. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Olanow CW; Obeso JA; Stocchi F
Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
[TBL] [Abstract][Full Text] [Related]
8. Influence of ageing on the pharmacokinetics of levodopa in elderly patients with Parkinson's disease.
Nagayama H; Ueda M; Kumagai T; Tsukamoto K; Nishiyama Y; Nishimura S; Hamamoto M; Katayama Y
Parkinsonism Relat Disord; 2011 Mar; 17(3):150-2. PubMed ID: 21172738
[TBL] [Abstract][Full Text] [Related]
9. Levodopa in Parkinson's Disease: Current Status and Future Developments.
Tambasco N; Romoli M; Calabresi P
Curr Neuropharmacol; 2018; 16(8):1239-1252. PubMed ID: 28494719
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Parkinson's disease.
Lieberman A
Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
[TBL] [Abstract][Full Text] [Related]
11. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Kondo T
J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
[TBL] [Abstract][Full Text] [Related]
12. Treatment of motor symptoms in advanced Parkinson's disease: a practical approach.
Maranis S; Tsouli S; Konitsiotis S
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1795-807. PubMed ID: 21645577
[TBL] [Abstract][Full Text] [Related]
13. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
Müller T; Kolf K; Ander L; Woitalla D; Muhlack S
Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980
[TBL] [Abstract][Full Text] [Related]
14. Treatment of levodopa-induced motor complications.
Stocchi F; Tagliati M; Olanow CW
Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
[TBL] [Abstract][Full Text] [Related]
15. An approach to the continuous dopaminergic stimulation in Parkinson's disease.
Schwartz M; Sabetay S
Isr Med Assoc J; 2012 Mar; 14(3):175-9. PubMed ID: 22675859
[TBL] [Abstract][Full Text] [Related]
16. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
Pagonabarraga J; Rodríguez-Oroz MC
Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
[TBL] [Abstract][Full Text] [Related]
17. Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.
Faulkner MA
Expert Opin Drug Saf; 2014 Aug; 13(8):1055-69. PubMed ID: 24962891
[TBL] [Abstract][Full Text] [Related]
18. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
Fernandez HH; Odin P
Curr Med Res Opin; 2011 May; 27(5):907-19. PubMed ID: 21351823
[TBL] [Abstract][Full Text] [Related]
19. Myths and realities of continuous dopaminergic stimulation.
Pirtošek Z
Psychiatr Danub; 2011 Mar; 23(1):80-3. PubMed ID: 21448103
[TBL] [Abstract][Full Text] [Related]
20. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
